Wedbush Downgrades Sutro Biopharma (NASDAQ:STRO) to Neutral
Sutro Biopharma (NASDAQ:STRO – Get Free Report) was downgraded by research analysts at Wedbush from an “outperform” rating to a “neutral” rating in a research note issued on Friday, MarketBeat.com reports. They presently have a $2.00 price target on the stock, down from their prior price target of $8.00. Wedbush’s price objective would indicate a […]
Sutro Biopharma (NASDAQ:STRO – Get Free Report) was downgraded by research analysts at Wedbush from an “outperform” rating to a “neutral” rating in a research note issued on Friday, MarketBeat.com reports. They presently have a $2.00 price target on the stock, down from their prior price target of $8.00. Wedbush’s price objective would indicate a […]
